Intercept Pharmaceuticals has nabbed the FDA’s breakthrough drug designation for obeticholic acid, a closely watched therapy in the pipeline for a blockbuster NASH indication.

…read more

Source: Intercept nabs a ‘breakthrough’ title for its blockbuster NASH contender